Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznana białaczka ostra (poza białaczką promielocytową) potwierdzona badaniem szpiku kostnego
- •Białaczka ostra, która nie reaguje na leczenie lub powróciła
- •Brak ograniczeń wieku i płci
- •Świadoma zgoda pacjenta lub opiekuna na udział w badaniu
✗ Disqualifies
- •Nowotwory inne niż białaczka wymagające leczenia
- •Pacjenci uznani przez lekarzy za niespełniających kryteriów badania
Simplified criteria — AI translation
Trial details
- Last updated (source)
- August 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Blood Hospital
Tianjin, China
Trial contact
hui wei, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.